KKR will acquire Integer Holdings in an all-cash transaction valued at $5.7 billion, taking the medical-device contract manufacturer private in what marks the firm's largest healthcare infrastructure bet this year. The deal removes a publicly traded supplier to cardiac-rhythm management and neuromodulation platforms from the market at a moment when device OEMs are rationalizing supply chains and private capital is betting on the picks-and-shovels layer of medical technology.
Integer manufactures components for implantable cardiac defibrillators, pacemakers, and neurostimulation devices. The company reported $1.47 billion in revenue for 2025, with operating margins in the low teens—a profile that suggests KKR is paying roughly 3.9x trailing sales. The premium to book value has not been disclosed, but Integer's market capitalization had hovered near $4.2 billion before acquisition rumors surfaced in late July. The deal includes assumption of Integer's existing debt, which stood at approximately $780 million as of the most recent quarter.
This is a supplier-consolidation thesis, not a technology play. Integer does not design end-user devices. It fabricates batteries, capacitors, enclosures, and feedthrough assemblies that go into products sold by Medtronic, Abbott, Boston Scientific, and others. KKR is betting that as those OEMs face margin pressure from reimbursement headwinds and commoditization in certain device categories, they will increasingly outsource manufacturing to scaled contract players. Integer's customer concentration—its top five clients represent approximately 68 percent of revenue—makes it a systemically important node in the cardiac and neuro device supply chain. That concentration is risk for a public equity holder. For a private-equity owner with a longer time horizon and the ability to re-contract terms, it is negotiating leverage.
The timing reflects a broader pattern. Over the past eighteen months, private equity has deployed more than $22 billion into healthcare services and medical technology infrastructure, according to PitchBook data through Q2 2026. These are not bets on clinical breakthroughs. They are bets on the durability of procedure volumes, the stickiness of supplier relationships, and the difficulty of switching costs in regulated manufacturing. Integer operates under ISO 13485 certification and FDA-registered facilities in five countries. Replicating that footprint takes years and hundreds of millions in capital expenditure. KKR is acquiring a moat, not a molecule.
Operators and allocators should watch three follow-on effects. First, whether Integer's OEM customers move to dual-source certain components in the twelve to eighteen months following close, a standard risk-mitigation response when a key supplier goes private. Second, whether KKR attempts to roll up smaller contract manufacturers in adjacent verticals—orthopedic implants and surgical instruments are the logical next domains—using Integer's compliance infrastructure as the platform. Third, whether this deal sets a new valuation floor for publicly traded peers like Miticon or TriMed, both of which have floated acquisition interest in the past six months.
The transaction is expected to close in Q4 2026, subject to regulatory approval and Integer shareholder vote. No financing details have been disclosed, but KKR's healthcare credit arm will likely provide part of the debt stack. The firm's existing portfolio includes surgical robotics supplier Lumenis and diabetes-monitoring platform DexCom, neither of which competes directly with Integer but both of which depend on similar supply-chain reliability. Integer will operate as a standalone entity under KKR ownership, with current management expected to remain in place. The deal does not include earn-outs or equity rollovers for Integer executives, which means KKR is paying full control value upfront.
The takeaway
KKR is paying 3.9x sales for a medical-device supplier with customer concentration risk that becomes negotiating power in private hands.
Want the 60-second program for your specific event?
Enter your event and email — we build it and send the branded proposal before lunch. No obligation.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori Press · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.